BridgeBio (BBIO) Q2 2025 Earnings Transcript

BridgeBio reported Q2 2025 revenue of $110.6 million, led by $71.5 million of U.S. Attruby net product revenue, which doubled sequentially from Q1 and was supported by 3,751 unique prescriptions and 120 weekly new patient adds. Management highlighted nearly 90% of U.S. patients paying $0 out of pocket, $756.9 million of cash and marketable securities, and reiterated that operating expenses should stay stable through year-end while revenue continues to grow. The company also pointed to upcoming Phase III readouts for ADH1 and LGMD2I in fall 2025 as key catalysts and described the ATTR-CM market as potentially reaching $15 billion to $20 billion at peak.

Analysis

BBIO is transitioning from a single-asset launch story into a multi-catalyst biotech re-rating, but the market is likely still underestimating how much of Attruby's growth is now self-reinforcing. The key second-order effect is that rising prescribing breadth creates a data flywheel: more volume supports more subgroup publications, which in turn lowers physician hesitation in both community and switch segments. That matters because this is not just share capture; it is category expansion, and the company is effectively using real-world evidence as a commercial weapon rather than a post-hoc validation tool.

The more interesting setup is the mismatch between commercial momentum and the implied duration of the story. Near-term, the stock can keep working if weekly adds and prescription breadth continue to inflect into 2H25, but the real optionality is in the fall readouts for ADH1 and LGMD2I. If either trial clears the company’s stated biomarker thresholds with clean safety, BBIO likely shifts from "launch multiple" to "platform multiple," because investors will start capitalizing a pipeline of follow-on indications rather than a narrow cardiomyopathy franchise.

The main risk is that the current launch narrative may be overly dependent on access mechanics and early-adopter enthusiasm. As the market broadens into community practices, payers and competitors can respond more aggressively on utilization management and contracting, which could slow incremental NBRx even if the total market remains healthy. There is also execution risk that the upcoming data set is directionally positive but not decisive enough to justify the current premium on pipeline optionality, especially if the market had already discounted a clean win.

Contrarian view: consensus is probably too focused on the visible launch slope and not enough on the asymmetry around the late-stage readouts. The stock could still have multiple expansion left if the fall data validates a second and third commercial franchise, but if those reads disappoint, the market may re-underwrite BBIO as a one-product company with elevated SG&A and a finite launch window. That makes the next 3-6 months a catalyst-dense period where the equity should trade more like a binary portfolio than a steady compounding story.

Key Decisions for Investors

• Long BBIO into the fall catalyst window (next 8-16 weeks) on the thesis that positive ADH1/LGMD2I data can re-rate the stock from single-asset launch story to multi-asset platform; target upside is multiple expansion, but keep risk tightly defined with a pre-event stop if launch metrics decelerate.
• Buy BBIO call spreads expiring after the ADH1 readout (e.g., 3-6 month tenor) to express upside convexity while limiting downside if the upcoming data are merely adequate rather than transformative.
• Pair trade: long BBIO / short PFE over 3-6 months — BBIO has self-help, launch momentum, and binary pipeline catalysts; PFE remains a lower-beta large-cap with less visible near-term inflection. Use this only if willing to tolerate event risk on the long leg.
• If you already own BBIO, trim 20-30% ahead of the first late-stage readout and re-add only on confirmation; the stock can gap on either outcome, so monetizing some of the launch-driven rerating before binary data is prudent.
• For more conservative accounts, wait for post-readout confirmation and then own BBIO on a breakout above the catalyst high; the cleaner risk/reward may come after volatility compresses rather than before the event.